

ASX Announcement: 7 July 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Optiscan Launches InSpecta™ Device for Veterinary Medicine

The first commercial launch of an Optiscan clinical device into the U.S. has commenced, with InSpecta™ now available in the large American veterinary healthcare market.

HIGHLIGHTS

- Optiscan has launched InSpecta™, its veterinary-first microscopic imaging device, in the U.S. market, following successful submission of its FDA dossier.
- InSpecta™ creates a new in-house imaging capability for veterinary practices, supporting faster clinical insight, workflow efficiency and potential new revenue opportunities.
- InSpecta™ is being showcased to veterinarians, specialists and industry decision-makers at the American Veterinary Medical Association (AVMA) Convention 2026 in Anaheim, California which is taking place over 10–14 July 2026.
- The launch of InSpecta™ means Optiscan has now brought its first clinical device to market, and creates a regulatory pathway that should support future product submissions.



Figure 1: Optiscan's InSpecta™ veterinary imaging device

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the 'Company') is pleased to announce the U.S. launch of InSpecta™, its veterinary-first microscopic imaging device, after successfully submitting its regulatory dossier to the U.S. Food and Drug Administration (FDA) Centre for Veterinary Medicine (CVM). The successful submission enables Optiscan to commence commercial sales activity in the U.S. and represents a pivotal milestone in the Company's transition from a technology and product developer to a commercial enterprise.

InSpecta™ will be launched and showcased at the American Veterinary Medical Association (AVMA) Convention 2026 in Anaheim, California, USA. This convention, which is taking place over 10-14 July 2026, gives Optiscan direct exposure to a wide sub-set of veterinary clinicians, specialists and practice decision-makers.

A MAJOR STRATEGIC MILESTONE ACHIEVED


The launch of InSpecta™ is a major commercial and strategic milestone for Optiscan. It is the first of the Company's clinical devices to have a full regulatory dossier submitted to the FDA for comment prior to formal release. Progress to market launch both validates Optiscan's underlying imaging platform and the Company's ability to navigate the regulatory requirements needed to access the broader U.S. healthcare market.

By entering the veterinary market, Optiscan is extending its proprietary imaging technology beyond human healthcare into a large and expanding sector where demand for advanced diagnostics, faster decision-making and in-house clinical capability continues to grow.


InSpecta™ is designed to address the gap between clinical examination and laboratory-based diagnostics by delivering real-time cellular imaging within the veterinary workflow, creating opportunities for improved patient care, greater workflow efficiency and new in-house service offerings.

UNLOCKING NEW POTENTIAL FOR VETERINARY MEDICINE


Built on Optiscan's proprietary imaging platform and purpose-designed for veterinary medicine, InSpecta™ delivers cellular-level visualisation in a compact, portable form factor suited to specialist hospitals, general practices, mobile services and field-based care. By bringing microscopic imaging to the point of care, the device supports more informed clinical decisions at the time they are needed, across a range of tissue types and pathologies.




Helicobacter in dog stomach




Sheep skeletal muscle showing muscle fibers




Mare uterine epithelium with longitudinal folds



Canine Mast Cell Tumour



Canine Oral Melanoma



Sheep cartilage showing chondrocytes

Figure 2: Examples of tissues imaged with the Optiscan InSpecta™

MEETING AN UNMET GLOBAL NEED

According to a Grand View Research-prepared report, the U.S. veterinary services market was valued at approximately US\$15.87 billion in 2024 and is projected to grow strongly through to 2033¹. Rising demand for advanced veterinary care, including the management of complex conditions such as cancer, is creating a need for technologies that can improve clinical insight, reduce diagnostic delays and support more efficient practice workflows.

\$15+
Billion

market size in the
United States

71%
of US
households
own a pet

\$30+
Billion

Projected U.S.
market size by 2033

Sources: Grand View Research 2025; American Pet Products Association, 2025

Figure 3: The U.S. veterinary market is large and growing

STRATEGIC SIGNIFICANCE

The commercial launch of Optiscan's InSpecta™ into the U.S. market is a key step in the Company's efforts to extend its proprietary imaging technology into veterinary medicine. It validates Optiscan's plans to diversify its growth opportunities and demonstrates the adaptability of the Company's platform across multiple healthcare markets. Importantly, it also establishes a U.S.-based commercial beachhead for Optiscan.

REGULATORY SIGNIFICANCE

The FDA CVM submission for InSpecta™ was a critical value inflection point for Optiscan's development and commercialisation strategy. It removed the principal regulatory hurdle to U.S. commercialisation of InSpecta™ and confirmed that the device had met the requirements necessary for market entry. The FDA CVM submission also strengthens Optiscan's regulatory capability, by providing a validated pathway and internal experience that can support future U.S. submissions across the Company's product pipeline.



Figure 4: FDA milestone progress for Optiscan InSpecta™

COMMERCIAL SIGNIFICANCE

Commercially, Optiscan's InSpecta™ gives the Company a product that meets FDA requirements with immediate access to the U.S. veterinary market. The device introduces a new in-house imaging capability for veterinary practices, supporting faster clinical decision-making, workflow efficiency and potential new revenue-generating services. By addressing a clear gap between clinical examination and laboratory diagnostics, InSpecta™ creates a platform for adoption across a broad range of veterinary settings while expanding the addressable market for Optiscan's medical technology portfolio.

CEO COMMENT

Optiscan CEO and Managing Director, Dr Camile Farah, said:

"The launch of Optiscan's InSpecta™ into the U.S. veterinary market is a defining development milestone for the Company. It comes hot on the heels of our FDA CVM submission for InSpecta™, and means we can now get cracking with the commercialisation of this device, which is targeting a slice of the world's largest veterinary healthcare market that is currently valued at more than US\$15 billion."

“Optiscan InSpecta™ has been designed specifically for veterinary practices servicing this large and growing U.S. market. It will deliver veterinarians immediate cellular insight at the point of care allowing them to offer advanced imaging capability in-house.”

“The U.S. launch of InSpecta™ validates the maturity of our imaging platform and establishes a repeatable regulatory and commercial pathway for other already revealed products that utilise our proprietary imaging technology. It represents one important step in Optiscan’s transition into a commercial-stage medical technology company – and more such steps are expected to follow as we continue to progress multiple human patient studies involving our other devices.”

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan’s patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan’s technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan’s medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

¹ <https://www.grandviewresearch.com/industry-analysis/us-veterinarians-market>